» Articles » PMID: 15596611

The Rate of Cognitive Decline in Parkinson Disease

Overview
Journal Arch Neurol
Specialty Neurology
Date 2004 Dec 15
PMID 15596611
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To measure the rate and predictors of change on the Mini-Mental State Examination in patients with Parkinson disease (PD) and to compare that change with the Mini-Mental State Examination changes of patients with Alzheimer disease and nondemented subjects.

Patients: Patients with PD were drawn from a community-based cohort in Rogaland County, Norway. Those who were without cognitive impairment at disease onset and participated in 1 or more assessments after visit 1 were included and examined after 4 years (visit 2) and 8 years (visit 3). Motor, cognitive, and psychiatric symptoms were rated using standardized scales at visit 1. Two population-based cohorts of patients with Alzheimer disease and nondemented control subjects were included for comparison. Data were analyzed using a mixed-effects model.

Results: One hundred twenty-nine PD patients (57% women) were included. The mean (SD) Mini-Mental State Examination score at visit 1 was 27.3 (5.7). The mean annual decline in score from visit 1 to visit 3 was 1.1 (95% confidence interval, 0.8 to 1.3; 3.9% change from visit 1). Patients with PD and dementia (n = 49) had an annual decline from visit 1 to visit 2 of 2.3 (95% confidence interval, 2.1 to 2.5; 9.1% change from visit 1), compared with 2.6 (95% confidence interval, 2.3 to 2.8; 10.6% change from visit 1) in the patients with Alzheimer disease (n = 34) (mean annual decline among patients with PD and dementia vs patients with Alzheimer disease, not significant). The change in score for nondemented PD patients (n = 80) was small and similar to that for nondemented control subjects (n = 1621). Old age, hallucinations, and more severe motor symptoms (rigidity and motor scores mediated by nondopaminergic lesions) at visit 1 were significantly associated with a more rapid cognitive decline in patients with PD.

Conclusions: The mean annual decline on the Mini-Mental State Examination for PD patients was 1 point. However, a marked variation was found. In patients with PD and dementia, the mean annual decline was 2.3, which was similar to the decline observed in patients with Alzheimer disease.

Citing Articles

Improvements in clinical signs and symptoms of Parkinson's disease using photobiomodulation: a five-year follow-up.

Liebert A, Bicknell B, Laakso E, Tilley S, Heller G, Kiat H BMC Neurol. 2024; 24(1):381.

PMID: 39385144 PMC: 11463085. DOI: 10.1186/s12883-024-03857-z.


Association of elevated cerebrospinal fluid levels of the longevity protein α-Klotho with a delayed onset of cognitive impairment in Parkinson's disease patients.

Zimmermann M, Fandrich M, Jakobi M, Roben B, Wurster I, Lerche S Eur J Neurol. 2024; 31(10):e16388.

PMID: 38946703 PMC: 11414814. DOI: 10.1111/ene.16388.


Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson's Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder.

Dautan D, Paslawski W, Montejo S, Doyon D, Marangiu R, Kaplitt M bioRxiv. 2024; .

PMID: 38712208 PMC: 11071367. DOI: 10.1101/2024.04.22.590542.


Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.

Jellinger K Int J Mol Sci. 2024; 25(1).

PMID: 38203667 PMC: 10778722. DOI: 10.3390/ijms25010498.


Dopamine in the prefrontal cortex plays multiple roles in the executive function of patients with Parkinson's disease.

Zhou Z, Yan Y, Gu H, Sun R, Liao Z, Xue K Neural Regen Res. 2023; 19(8):1759-1767.

PMID: 38103242 PMC: 10960281. DOI: 10.4103/1673-5374.389631.